 |
|
The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney DiseaseA Systematic Review and Meta-analysis
Fiona M. Clement, PhD;
Scott Klarenbach, MD, MSc;
Marcello Tonelli, MD, SM;
Jeffrey A. Johnson, PhD;
Braden J. Manns, MD, MSc
Arch Intern Med. 2009;169(12):1104-1112.
Background Treatment of anemia in chronic kidney disease (CKD) with erythropoietin-stimulating agents (ESAs) is commonplace. The optimal hemoglobin treatment target has not been established. A clearer understanding of the health-related quality of life (HQOL) impact of hemoglobin target levels is needed. We systematically reviewed the randomized controlled trial (RCT) data on HQOL for patients treated with low to intermediate (9.0-12.0 g/dL) and high hemoglobin target levels (>12.0 g/dL) and performed a meta-analysis of all available 36-item short-form (SF-36) RCT data.
Methods We conducted a search to identify all RCTs of ESA therapy in patients with anemia associated with CKD (1966–December 2006). Inclusion criteria were (1) 30 or more participants, (2) anemic adults with CKD, (3) epoetin (alfa and beta) or darbepoetin used, (4) a control arm, and (5) reported HQOL using a validated measure. All available SF-36 data underwent meta-analysis using the weighted mean difference.
Results Of 231 full texts screened, 11 eligible studies were identified. The SF-36 was used in 9 trials. Reporting of these data was generally incomplete. Data from each domain of the SF-36 were summarized. Statistically significant changes were noted in the physical function (weighted mean difference [WMD], 2.9; 95% confidence interval [CI], 1.3 to 4.5), general health (WMD, 2.7; 95% CI, 1.3 to 4.2), social function (WMD, 1.3; 95% CI, –0.8 to 3.4), and mental health (WMD, 0.4; 95% CI, 0.1 to 0.8) domains. None of the changes would be considered clinically significant.
Conclusions Our study suggests that targeting hemoglobin levels in excess of 12.0 g/dL leads to small and not clinically meaningful improvements in HQOL. This, in addition to significant safety concerns, suggests that targeting treatment to hemoglobin levels that are in the range of 9.0 to 12.0 g/dL is preferred.
Author Affiliations: Departments of Community Health Sciences and Medicine and Centre for Health and Policy Studies, University of Calgary, Calgary, Alberta, Canada (Drs Clement and Manns); Department of Medicine, Division of Nephrology, University of Alberta, Edmonton (Drs Klarenbach and Tonelli); and Institute for Health Economics, Edmonton, Alberta (Dr Johnson).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(12):1094.
FULL TEXT
Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life
Shahriar Moossavi and Barry I. Freedman
Arch Intern Med. 2009;169(12):1100-1101.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients
Johansen et al.
Nephrol Dial Transplant 2011;0:gfr697v1-gfr697.
ABSTRACT
| FULL TEXT
Prevalence, characteristics and prognostic significance of anemia in daily practice
Terrier et al.
QJM 2011;0:hcr230v1-hcr230.
ABSTRACT
| FULL TEXT
Changes in quality of life over time--Dutch haemodialysis patients and general population compared
Mazairac et al.
Nephrol Dial Transplant 2011;26:1984-1989.
ABSTRACT
| FULL TEXT
Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease: A Randomized Trial
Lewis et al.
CJASN 2011;6:845-855.
ABSTRACT
| FULL TEXT
2009: A Requiem for rHuEPOs--But Should We Nail Down the Coffin in 2010?
Goldsmith
CJASN 2010;5:929-935.
ABSTRACT
| FULL TEXT
Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life
Moossavi and Freedman
Arch Intern Med 2009;169:1100-1101.
FULL TEXT
All you need to read in the other general journals
BMJ 2009;338:b2511-b2511.
FULL TEXT
|
